Splash
Verona Pharma

Breath of Innovation

Verona Pharma is developing life enhancing treatments for respiratory diseases.
Splash
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

Funding to support Phase 3 ENHANCE clinical program in COPD THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, COVID-19, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.

COPD
The unmet need

COPD

COVID-19

Cystic Fibrosis

Asthma

Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the World Health Organization.

Find out more

Latest Film

Verona Pharma's novel COPD candidate "has the potential to significantly benefit patients," believes CMO Dr Kathleen Rickard

The Company expects to hold an End-of-Phase 2 meeting with the US FDA in the second quarter and anticipates starting Phase 3 later this year.

Play

Splash

© Verona Pharma plc 2020. All rights reserved